COLL vs VERX: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

VERX is the larger of the two ($2.83B market cap): the incumbent the market prices for continued execution (16.75x forward earnings, beta 0.75). COLL is the smaller challenger ($777.20M), cheaper on forward earnings (3.53x): more room to run, but more to prove. If you believe in growth, VERX fits: analysts expect its revenue to rise 10% next year, against 2% for COLL. If you believe in paying less for profit, COLL fits: it trades at 3.53x forward earnings, against 16.75x for VERX.

COLL vs VERX: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCOLLVERXWhat it tells you
Market cap$777.20M$2.83BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E3.5316.75Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.730.75Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range12% of range68% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.6215.05How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: COLL is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how COLL and VERX affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COLL and VERX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COLL and VERX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Collegium Pharmaceutical (COLL) do?

Collegium Pharmaceutical, based in Stoughton, Massachusetts, sells branded prescription drugs in the US. It does not discover new molecules; it buys approved brands and runs them with its own sales force. The pain portfolio covers Belbuca (buprenorphine buccal film), Xtampza ER (abuse-deterrent extended-release oxycodone) and the Nucynta franchise (tapentadol). The ADHD side came through two deals: the 2024 purchase of Ironshore, which brought Jornay PM, an evening-dosed methylphenidate, and the May 2026 purchase of Azstarys (serdexmethylphenidate and dexmethylphenidate) from Corium for about $656 million in cash plus up to $135 million in milestones.

Full COLL guide

What does Vertex (VERX) do?

Vertex, Inc. (NASDAQ: VERX) is a global provider of indirect tax software, content, and services that help large and mid-size enterprises calculate, collect, and report taxes such as sales and consumer use tax, value added tax (VAT), and payroll-related indirect taxes. Its core O Series platform plugs into the ERP, e-commerce, procurement, and billing systems that big companies already run (SAP, Oracle, Workday, Salesforce and others) and applies a continuously updated database of tax rules across thousands of jurisdictions so that the correct tax is applied on every transaction. Founded in 1978 and public since 2020, Vertex serves roughly 4,900 direct customers, many of them large multinationals, and earns the bulk of its revenue from recurring software subscriptions plus related services, with annual recurring revenue per customer of about $137,867 as of late 2025.

Full VERX guide

COLL vs VERX: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • COLL drivers: Jornay PM share gains in ADHD; Azstarys as a second ADHD brand.
  • VERX drivers: Recurring, mission-critical tax compliance; Cloud migration and higher-value expansion.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The largest risk is the pace of pain-portfolio decline. For VERX, vertex shares fell sharply from late 2025 into 2026, driven by deteriorating key performance indicators, extended sales cycles, and reduced growth and margin expectations.

COLL or VERX: which should you pick?

If the story you believe is COLL's (Jornay PM share gains in ADHD), COLL is the more direct way to own it; if it is VERX's (Recurring, mission-critical tax compliance), VERX is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COLL and VERX guides.

COLL vs VERX: the full fundamentals

COLL. Figures combine the fourth quarter of 2025 with the first nine months of 2026, at a share price of about $25.03 on November 20, 2026 and about 31.1 million shares outstanding. Adjusted figures exclude large non-cash items, mainly about $55 million a quarter of amortization on acquired drug rights, which is why GAAP diluted EPS for the first nine months of 2026 was only about $0.64 and the trailing GAAP P/E is near 23. A multiple near 3 times adjusted earnings is low for a profitable drug company and shows how much the market discounts the pain brands. The $239 million of convertible notes convert at about $36.56 a share, well above the current price.

VERX. As of November 20, 2026, Vertex traded at a market cap of about $2.8 billion, roughly 3.5 times trailing revenue and about 17 times 2027 earnings estimates, up from about 2.7 times sales and 13 times forward earnings in mid-October after the Q3 beat lifted the shares. There is no meaningful trailing P/E because GAAP results swung to a loss in Q3, so the forward multiple and adjusted EBITDA (guided to about $218-220 million for 2026) are the more useful gauges while restructuring savings ramp. The 13 analysts in Yahoo's count have a mean target near $21.

Headline figures (approximate, November 2026): COLL shows revenue (ttm) ~$815 million (+3.3% YoY in Q3), q3 2026 adjusted eps $1.96 vs ~$1.86 consensus, adjusted ebitda (ttm) ~$467 million, adjusted eps (ttm) ~$7.67; VERX shows market cap ~$2.8 billion, revenue (ttm) ~$809 million, revenue growth (q3 2026, yoy) ~11%, q3 2026 revenue ~$213 million (adj. EPS $0.26 vs $0.22 est.).

The bottom line: COLL vs VERX

COLL and VERX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined COLL and VERX exposure against your real portfolio. It is not an investment adviser.

Wondering how COLL or VERX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Collegium Pharmaceutical

Ask Walnut's AI anything about COLL and see how it fits what you own.

FAQ

What is the difference between COLL and VERX?

+

Collegium Pharmaceutical, based in Stoughton, Massachusetts, sells branded prescription drugs in the US. Vertex, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is COLL or VERX the better stock?

+

Neither is universally better. VERX is the larger incumbent; COLL is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, COLL or VERX?

+

On forward P/E (as of November 2026), COLL trades at 3.53x and VERX at 16.75x, so COLL is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both COLL and VERX?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of COLL vs VERX?

+

COLL: The largest risk is the pace of pain-portfolio decline. Nucynta revenue fell 44% in a year once generics arrived, and a 2018 settlement allows Teva to sell a generic Belbuca from January 23, 2027 if it has FDA approval. Belbuca was about $222 million of 2025 revenue, so a launch would cut deeply into cash flow. Ascent Pharmaceuticals has also filed to challenge Belbuca's 2032 patent. Xtampza ER faces payer pressure. Opioid exposure brings legal risk: several dozen third-party payors sued Collegium and others in July 2026, alleging Nucynta and Xtampza ER were promoted to encourage continued prescribing, and several state attorneys general have open investigations. ADHD stimulants are Schedule II drugs, so DEA production quotas and shortages can limit supply. The balance sheet carries about $1.08 billion of debt plus a Jornay royalty obligation at about 13.5% effective interest, and cash fell from about $387 million at the end of 2025 to $145 million after the Azstarys purchase. Operating expenses rose 44% in the third quarter, and further acquisitions add integration risk. The stock is small and has been volatile, falling about 17% after the August report and about 45% so far in 2026. Analysts expect revenue of about $848 million in 2027 but adjusted EPS to fall about 5% to roughly $7.08, which reflects the Belbuca generic risk. VERX: Vertex shares fell sharply from late 2025 into 2026, driven by deteriorating key performance indicators, extended sales cycles, and reduced growth and margin expectations. They have rebounded about 29% over the three months to November 20, 2026 after a Q3 beat, but remain about 11% lower over one year, so sentiment can swing quickly in either direction. A CEO transition adds leadership and execution uncertainty at a moment when the company is also restructuring, and a botched reset could pressure both revenue and morale. Growth has settled around 10% from higher prior levels, and if enterprise buyers keep delaying decisions, subscription growth could slow further; management also expects net revenue retention to slip about a point in Q4 after losing a payroll-tax OEM partner, and SAP's extended 2027 migration deadline may push some demand later. Competition is intense from larger and well-funded rivals (including Avalara, Thomson Reuters ONESOURCE, Sovos, and Wolters Kluwer), which can pressure pricing and win rates. GAAP profitability is weak relative to adjusted EBITDA (a trailing net loss of about $47 million, including a Q3 2026 GAAP loss of about $47 million, and an operating margin near 3%) because of stock-based compensation, amortization and other charges, and debt of about $350 million exceeds cash of about $218 million. Several plaintiff law firms have publicized investigations following the stock decline, which, while common after large drops, add headline and potential litigation noise.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell COLL or VERX; figures are approximate and dated (as of November 2026). Verify current data before investing.